Syneos Health
Overview
Syneos Health is a global biopharmaceutical services company that provides clinical research, regulatory affairs, and commercial solutions to pharmaceutical, biotechnology, and medical device manufacturers. Headquartered in Morrisville, North Carolina, the company operates as a contract research organization (CRO) and contract sales organization (CSO), with a workforce exceeding 28,000 employees across more than 100 countries. Founded in 2010 through the establishment of INC Research and subsequently expanded via the 2018 merger with Syneos (formerly Evernorth), the organization generates approximately $5.4 billion in annual revenue and maintains a market capitalization around $5.2 billion as of 2024. Within the neurodegeneration research landscape, Syneos Health functions as a critical infrastructure partner facilitating the translation of basic neuroscience discoveries into clinical therapies for diseases including Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis (ALS), and other progressive neurological conditions.
Function/Biology
...Syneos Health
Overview
Syneos Health is a global biopharmaceutical services company that provides clinical research, regulatory affairs, and commercial solutions to pharmaceutical, biotechnology, and medical device manufacturers. Headquartered in Morrisville, North Carolina, the company operates as a contract research organization (CRO) and contract sales organization (CSO), with a workforce exceeding 28,000 employees across more than 100 countries. Founded in 2010 through the establishment of INC Research and subsequently expanded via the 2018 merger with Syneos (formerly Evernorth), the organization generates approximately $5.4 billion in annual revenue and maintains a market capitalization around $5.2 billion as of 2024. Within the neurodegeneration research landscape, Syneos Health functions as a critical infrastructure partner facilitating the translation of basic neuroscience discoveries into clinical therapies for diseases including Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis (ALS), and other progressive neurological conditions.
Function/Biology
Syneos Health operates through an integrated "FullCourt" operating model combining clinical development services with commercial capabilities. In the context of neurodegeneration research, the company designs and executes clinical trials assessing therapeutic candidates targeting pathological processes including amyloid-beta aggregation, tau pathology, alpha-synuclein accumulation, and neuroinflammatory cascades. Their clinical research divisions manage patient recruitment, biomarker monitoring, endpoint assessment, and adverse event surveillance. The company employs specialized expertise in neurodegenerative disease phenotyping, cognitive assessment protocols, and biofluid biomarker collection—including cerebrospinal fluid (CSF) and blood-based biomarkers such as phosphorylated tau variants (p-tau181, p-tau217), amyloid-beta 42, and neurofilament light chain (NfL). Syneos Health maintains dedicated therapeutic expertise units focused on neurodegeneration, employing neuroscientists, clinical neurologists, and biostatisticians who understand disease pathobiology and trial design optimization for progressive neurological conditions.
Role in Neurodegeneration
Syneos Health supports neurodegenerative disease research through comprehensive trial management services encompassing site selection, investigator training, and regulatory coordination for early-phase (Phase I-II) biomarker validation studies through late-stage (Phase III) clinical efficacy trials. The company has managed pivotal trials for disease-modifying therapies targeting Alzheimer's disease, including amyloid-targeting monoclonal antibodies and tau-directed interventions. Their services extend to rare neurodegenerative conditions including frontotemporal dementia, progressive supranuclear palsy, and neuroinflammatory disorders, where patient population scarcity necessitates specialized recruitment and retention strategies. By providing integrated services—from protocol development through commercialization support—Syneos Health accelerates the development timeline for neuroprotective and disease-modifying therapeutic candidates, thereby supporting the translation of mechanistic insights into accessible clinical interventions.
Molecular Mechanisms
Syneos Health's involvement in neurodegeneration research centers on facilitating investigations into molecular disease mechanisms rather than discovering them independently. The company supports biomarker-driven trial designs measuring specific pathological processes. This includes monitoring proteopathic cascades (protein misfolding and aggregation) through structural biomarkers and measuring neuraxonal injury via neurofilament quantification. Their expertise encompasses correlating systemic biomarkers with central nervous system pathology, supporting the validation of blood-based surrogates for brain amyloidosis and tauopathy. The company utilizes advanced neuroimaging analysis, positron emission tomography (PET) quantification of amyloid and tau burden, and magnetic resonance imaging (MRI) assessment of neurodegeneration progression, providing objective outcome measures for clinical trials.
Clinical/Research Significance
Syneos Health's infrastructure substantially impacts neurodegeneration research efficiency and data quality. By standardizing trial protocols, harmonizing biomarker collection methodologies, and implementing rigorous data management systems, the company reduces trial heterogeneity and enhances statistical power. Their global reach enables multinational trials incorporating diverse genetic backgrounds and environmental exposures, improving external validity of neurodegeneration research findings.
Related organizations include competitor CROs (Parexel, IQVIA, Charles River Laboratories), academic medical centers conducting neurodegenerative disease research, pharmaceutical manufacturers developing neurotrophic and neuroprotective therapeutics, and regulatory agencies (FDA, EMA) establishing neurodegeneration trial guidelines.